Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: Platelet responsiveness and clinical outcome

Korean Circulation Journal

Volumn 42, Issue 6, 2012, Pages 382-389

  Yu, Long Hao ^a,b   Kim, Moo Hyun ^a,b   Zhang, Hong Zhe ^a,b   Park, Jong Seong ^a   Park, Tae Ho ^a   Kim, Young Dae ^a   Cha, Kwang Soo ^c   Han, Jin Yeong ^a  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

Author keywords

Coronary artery disease; Drug eluting stents; Platelet function tests

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; ASPIRIN REACTION UNIT; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; P2Y12 REACTION UNIT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET RESPONSIVENESS; PREDICTIVE VALUE; SEX DIFFERENCE; STENT THROMBOSIS; THROMBOCYTE FUNCTION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84864006397     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2012.42.6.382     Document Type: Article

References (27)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16. (Pubitemid 46517957)
2. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009;103(3 Suppl):A27-34.
3. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009;102:7-14.
4. Angiolillo DJ. Platelet function testing in clinical practice: are we ready for prime time? Rev Esp Cardiol 2009;62:113-6.
5. Capodanno D, Angiolillo DJ. Platelet monitoring for PCI: which test is the one to choose? Hamostaseologie 2009;29:376-80.
6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. (Pubitemid 350106708)
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
8. Tantry US, Gurbel PA. Platelet monitoring for PCI: is it really necessary? Hamostaseologie 2009;29:368-75.
9. Campo G, Fileti L, Valgimigli M, et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 2010;30:319-31.
10. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
11. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5. (Pubitemid 32721947)
12. Aradi D, Komócsi A Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543-51.
13. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study. J Am Coll Cardiol 2008;52:1128-33.
14. Woo KS, Kim BR, Kim JE, et al. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Korean J Lab Med 2010;30:460-8.
15. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011;106:211-8.
16. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010;8:37-42.
17. Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008;6:54-61.
18. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
19. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339-43.
20. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50. (Pubitemid 44648629)
21. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280-9.
22. Ko YG, Suh JW, Kim BH, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383-90.
23. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
24. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66. (Pubitemid 46205039)
25. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5. (Pubitemid 44522148)
26. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009;104:525-30.
27. Lee SP, Park KW, Shin DH, et al. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug eluting stent implantation for coronary heart study: result from the CILON-T randomized trial POCT substudy. J Atheroscler Thromb 2011;18:914-23.